Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 2, 2010, Pages 599-608

  Bender, Gregor ^a,b   Florian Jr , Jeffry A ^b   Bramwell, Stephen ^c   Field, Mark J ^c   Tan, Keith K C ^c   Marshall, Scott ^c   DeJongh, Joost ^d   Bies, Robert R ^b,e   Danhof, Meindert ^a,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d LAP and P Consultants BV   (Netherlands)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREGABALIN; SILDENAFIL; SODIUM CHLORIDE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG RESPONSE; MALE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

ANALGESICS; ANIMALS; CALCIUM CHANNELS; CHRONIC DISEASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DRUG INTERACTIONS; GAMMA-AMINOBUTYRIC ACID; HYPERALGESIA; ION CHANNEL GATING; LIGANDS; MALE; MODELS, BIOLOGICAL; PAIN; PAIN THRESHOLD; PIPERAZINES; PURINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONES;

EID: 77954894230     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.166074     Document Type: Article

References (40)

1. Antoniu SA (2006) Sildenafil citrate for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 7:825-828.
2. Backonja MM, Irving G, and Argoff C (2006) Rational multidrug therapy in the treatment of neuropathic pain. Curr Pain Headache Rep 10:34-38.
3. Beal B and Sheiner L (1992) NONMEM User's Guide, Part I, University of California, San Francisco.
4. Beal SL (2002) Commentary on significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 29:403-410; discussion 411-412.
5. Bender G, Gosset J, Florian J, Tan K, Field M, Marshall S, DeJongh J, Bies R, and Danhof M (2009) Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical study design. Pharm Res 26:2259-2269.
6. Briganti A, Salonia A, Deho' F, Zanni G, Barbieri L, Rigatti P, and Montorsi F (2005) Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. World J Urol 23:374-384. (Pubitemid 43124388)
7. Chong MS and Brandner B (2006) Neuropathic agents and pain. New strategies. Biomed Pharmacother 60:318-322.
8. Danhof M, de Jongh J, De Lange EC, Della Pasqua O, Ploeger BA, and Voskuyl RA (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.Annu Rev Pharmacol Toxicol 47:357-400.
9. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, and Voskuyl RA (2008) Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 29:186-191.
10. 2+ channel α2δ ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 28:75-82.
11. Ette EI (1997) Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486-495.
12. Ette EI, Howie CA, Kelman AW, and Whiting B (1995a) Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies. Pharm Res 12:729-737.
13. Ette EI, Kelman AW, Howie CA, and Whiting B (1995b) Analysis of animal pharmacokinetic data: performance of the one point per animal design. J Pharmacokinet Biopharm 23:551-566.
14. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, and Capparelli EV (2003) Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 43:610-623.
15. Field MJ and Williams RG (2008) inventors; Pfizer Inc., assignee; Synergistic combinations of an α-2-δ ligand and a cGMP phosphodiesterase 5 inhibitor. U.S. patent 7,419,981. 2008 Sept. 2.
16. Field MJ, McCleary S, Hughes J, and Singh L (1999) Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 80:391-398.
17. Francis DA, Christopher AT, and Beasley BD (2006) Conservative treatment of peripheral neuropathy and neuropathic pain. Clin Podiatr Med Surg 23:509-530.
18. Fuseau E and Sheiner LB (1984) Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin Pharmacol Ther 35:733-741. (Pubitemid 14077476)
19. Guay DR (2005) Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? Am J Geriatr Pharmacother 3:274-287.
20. Gilron I and Max MB (2005) Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev Neurother 5:823-830.
21. Gilron I, Watson CP, Cahill CM, and Moulin DE (2006) Neuropathic pain: a practical guide for the clinician. CMAJ 175:265-275.
22. Hamandi K and Sander JW (2006) Pregabalin: a new antiepileptic drug for refractory epilepsy. Seizure 15:73-78.
23. Harden N and Cohen M (2003) Unmet needs in the management of neuropathic pain. J Pain Symptom Manage 25 (Suppl 5):S12-S17.
24. Hitiris N and Brodie MJ (2006) Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol 19:175-180.
25. Jackson G, Gillies H, and Osterloh I (2005) Past, present, and future: a 7-year update of Viagra (sildenafil citrate). Int J Clin Pract 59:680-691.
26. Jackson KC 2nd (2006) Pharmacotherapy for neuropathic pain. Pain Pract 6:27-33.
27. Jensen MP, Chodroff MJ, and Dworkin RH (2007) The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 68:1178-1182.
28. Jonker DM, Visser SA, van der Graaf PH, Voskuyl RA, and Danhof M (2005) Toward a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther 106:1-18.
29. Lauria-Horner BA and Pohl RB (2003) Pregabalin: a new anxiolytic. Expert Opin Investig Drugs 12:663-672.
30. Mandema JW, Verotta D, and Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20:511-528.
31. Nurmikko TJ and Haanpää M (2005) Treatment of postherpetic neuralgia. Curr Pain Headache Rep 9:161-167.
32. Parke J, Holford NH, and Charles BG (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 59:19-29.
33. Sheiner LB, Rosenberg B, and Marathe VV (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 5:445-479. (Pubitemid 8224518)
34. Stillman M (2006) Clinical approach to patients with neuropathic pain. Cleve Clin J Med 73:726-728, 729-730, 733-736 passim.
35. Van der Graaf PH and Danhof M (1997) Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modeling. Int J Clin Pharmacol Ther 35:442-446.
36. Wade JR, Beal SL, and Sambol NC (1994) Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. J Pharmacokinet Biopharm 22:165-177.
37. Wählby U, Jonsson EN, and Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231-252.
38. Wählby U, Jonsson EN, and Karlsson MO (2002) Comparison of stepwise covariate model building strategies in population pharmacokinetic- pharmacodynamic analysis. AAPS Pharmsci 4:E27.
39. Yano Y, Beal SL, and Sheiner LB (2001) Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171-192.
40. Zareba G (2005) Pregabalin: a new agent for the treatment of neuropathic pain. Drugs Today (Barc) 41:509-516.